Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00138060
Status:
COMPLETED
Last Update Posted:
2010-07-20
First Post:
2005-08-26
Brief Title:
ToxicityBenefit Ratio Optimization of Chemotherapy in Colorectal Cancer CRC Patients by Determination of Individual Genotypic Determinants
Sponsor:
Institut de Recherche Clinique sur les Cancers et le Sang
Organization:
Institut de Recherche Clinique sur les Cancers et le Sang
Study Overview
Official Title:
Protocole Evaluant Chez Des Patients Porteurs de Cancers Colorectaux Metastatiques lInteret Des Determinants Genotypiques Pour lOptimisation de lEfficacite et de la Tolerance de la Chimiotherapie Par Irinotecan et 5-fluorouracile
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to optimize a fluorouracilirinotecan chemotherapy regimen by the identification of individual thymidylate synthase TS and UDP-glucuronosyltransferase 1 UGT1A1 polymorphisms before the first administration
The results of this identification determine the chemotherapy type high-dose irinotecan or not
The results of this identification determine the chemotherapy type high-dose irinotecan or not
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None